Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 DDI Study with Repaglinide, Atorvastatin, Digoxin, and Rosuvastatin
NCT06601517Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of conveglipron in Overweight and obesity, sponsored by Huadong Medicine. Primary endpoints: Area Under the Curve from time zero to infinity, Area Under the Curve from time zero to last quantifiable concentration and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06601517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601517.